ARCHIVES

ODAC Votes to Nix Amgen’s Drug Xgeva For Proposed Prostate Cancer Indication

This article is from The Cancer Letter archive.

Vol. 38 No. 07 | February 17, 2012

Download PDF Visit The Full Archive

Related Articles

Doxil/Caelyx Survival 3 Weeks Longer Than Topotecan

November 28, 2003

Researchers Link Cancer Risk And DMPA Birth Control Use

April 27, 2012

Rauscher Summarizes Criticism of Cooperative Groups; Changes To Await May 22024 Conference

May 9, 1975

ACS, NBCC Weigh Involvement In March, Ask What Happens Next

October 31, 1997

DOD Bill Passes Senate; Prostate Cancer Gets $75 Mil.; Breast Cancer Recieves $175 Mil.

June 25, 1999

Breast Cancer Report To The Profession Suddenly Is a Report To The Nation; Treatment Progress Noted

October 4, 1974